BB Biotech AG lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,265,304 shares of the biopharmaceutical company’s stock after purchasing an additional 515,472 shares during the quarter. Halozyme Therapeutics accounts for approximately 3.2% of BB Biotech AG’s investment portfolio, making the stock its 11th biggest holding. BB Biotech AG owned 6.43% of Halozyme Therapeutics worth $105,961,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Halozyme Therapeutics by 4.8% in the second quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock worth $148,652,000 after purchasing an additional 532,658 shares in the last quarter. Iridian Asset Management LLC CT lifted its position in shares of Halozyme Therapeutics by 2.0% in the second quarter. Iridian Asset Management LLC CT now owns 10,608,993 shares of the biopharmaceutical company’s stock worth $136,007,000 after purchasing an additional 208,605 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Halozyme Therapeutics by 9.5% in the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after purchasing an additional 831,654 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Halozyme Therapeutics by 6.1% in the first quarter. JPMorgan Chase & Co. now owns 2,915,415 shares of the biopharmaceutical company’s stock worth $37,784,000 after purchasing an additional 168,349 shares in the last quarter. Finally, Snyder Capital Management L P lifted its position in shares of Halozyme Therapeutics by 8.1% in the first quarter. Snyder Capital Management L P now owns 2,318,433 shares of the biopharmaceutical company’s stock worth $30,047,000 after purchasing an additional 173,884 shares in the last quarter. 85.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Halozyme Therapeutics, Inc. (HALO) traded down 0.30% during trading on Friday, reaching $16.55. 348,636 shares of the company were exchanged. The firm’s 50 day moving average price is $13.01 and its 200 day moving average price is $13.28. Halozyme Therapeutics, Inc. has a one year low of $8.18 and a one year high of $17.55. The company’s market capitalization is $2.22 billion.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. During the same quarter last year, the business posted ($0.21) earnings per share. Halozyme Therapeutics’s revenue was up 1.2% on a year-over-year basis. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post ($0.22) earnings per share for the current fiscal year.

A number of analysts have recently commented on the stock. BidaskClub lowered shares of Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Friday, August 11th. Canaccord Genuity set a $16.00 price objective on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Jefferies Group LLC reissued an “underperform” rating and issued a $7.00 price objective (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $16.00.

ILLEGAL ACTIVITY NOTICE: “BB Biotech AG Increases Stake in Halozyme Therapeutics, Inc. (HALO)” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/bb-biotech-ag-increases-stake-in-halozyme-therapeutics-inc-halo/1580609.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.